Jump to:
Solvonis Therapeutics PLC Fundamentals
| Company Name | Solvonis Therapeutics PLC | Last Updated | 2025-03-28 |
|---|
| Industry | Specialty Industrial Machinery | Sector | Industrials |
|---|
| Shares in Issue | 2.296 bn | Market Cap | £3.56 m |
|---|
| PE Ratio | 0.00 | Dividend per Share | 0 |
|---|
| Dividend Yield | 0 | Dividend Cover | 0 |
|---|
| EPS | -£0.03 | EPS Growth (%) | 0 |
|---|
| PEG | 0 | DPS Growth (%) | 0 |
|---|
| Debt Ratio | 0 | Debt Equity Ratio | 0 |
|---|
| Asset Equity Ratio | 1.0422 | Cash Equity Ratio | 0.2873 |
|---|
| Quick Ratio | 9.7246 | Current Ratio | 9.72 |
|---|
| Price To Book Value | 1.0877 | ROCE | 0 |
|---|
Solvonis Therapeutics PLC Dividends
| Type | Ex-Date | Pay Date | Currency | Net Dividend | Year Total |
|---|
Solvonis Therapeutics PLC Company Financials
| Assets | 2023 | 2022 |
|---|
| Tangible Assets | £39,000.00 | £701,000.00 |
| Intangible Assets | £2.07 m | £2.07 m |
| Investments | 0 | 0 |
| Total Fixed Assets | £2.12 m | £2.78 m |
| Stocks | £51,000.00 | £187,000.00 |
| Debtors | £71,000.00 | £43,000.00 |
| Cash & Equivalents | £155,000.00 | £1.64 m |
| Other Assets | 0 | 0 |
| Total Assets | £2.43 m | £4.94 m |
| Liabilities | 2023 | 2022 |
|---|
| Creditors within 1 year | £386,000.00 | £367,000.00 |
| Creditors after 1 year | £22,000.00 | £18,000.00 |
| Other Liabilities | 0 | 0 |
| Total Liabilities | £408,000.00 | £385,000.00 |
| Net assets | £2.03 m | £4.55 m |
| Equity | 2023 | 2022 |
|---|
| Called up share capital | £41,000.00 | £41,000.00 |
| Share Premium | £9.50 m | £9.50 m |
| Profit / Loss | -£3.12 m | -£2.71 m |
| Other Equity | £2.03 m | £4.55 m |
| Preference & Minorities | 0 | 0 |
| Total Capital Employed | £2.03 m | £4.55 m |
| Ratios | 2023 | 2022 |
|---|
| Debt Ratio | £0.01 | £0.00 |
| Debt-to-Equity | £0.01 | £0.00 |
| Assets / Equity | 1.0422 | 1.0422 |
| Cash / Equity | 0.2873 | 0.2873 |
| EPS | -£0.02 | -£0.03 |
| Cash Flow | 2023 | 2022 |
|---|
| Cash from operating activities | -£1.24 m | -£2.36 m |
| Cashflow before financing | -£1.24 m | £1.77 m |
| Increase in Cash | -£1.47 m | £1.06 m |
| Income | 2023 | 2022 |
|---|
| Turnover | £587,000.00 | £542,000.00 |
| Cost of sales | £329,000.00 | £242,000.00 |
| Gross Profit | £258,000.00 | £300,000.00 |
| Operating Profit | -£3.12 m | -£2.70 m |
| Pre-Tax profit | -£3.12 m | -£2.71 m |
Solvonis Therapeutics PLC Company Background
| Sector | Industrials |
|---|
| Activities | Solvonis Therapeutics PLC, formerly Graft Polymer (UK) PLC focuses on the development of polymer modification and drug delivery systems. It has licensed its Drug Delivery System platform IP to MGC Pharmaceuticals in relation to MGC Pharma's CimetrA product. The group's products address customer needs across a wide range of end-use markets, from automotive through to medical, and are not dependent on one market segment. The Company operates in two business segments being polymer development and production in Slovenia. |
|---|
| Latest Interim Date | 13 Sep 2024 |
|---|
| Latest Fiscal Year End Date | 30 Apr 2024 |
|---|
Solvonis Therapeutics PLC Directors
| Appointed | Name | Position |
|---|
| 2024-09-26 | Mr. Dennis J. Purcell | Non-Executive Director,Chairman |
| 2024-09-26 | Mr. Roby Zomer | Non-Executive Director,Chairman |
| 2024-08-01 | Mr. Victor Bolduev | Executive Director,Chief Technical Officer |
| 2024-08-12 | Ms. Yifat Steuer | Executive Director,Chief Financial Officer |
| 2024-07-15 | Mr. Pavel Kobzev | Executive Director,Chief Marketing Officer |
| 2024-06-28 | Mr. Alexander Samuel Brooks | Non-Executive Director |
| 2024-07-10 | Mr. Nicholas Nelson | Non-Executive Director |
Solvonis Therapeutics PLC Contact Details
Solvonis Therapeutics PLC Advisors
